Overview
Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.
Current Appointments & Affiliations
James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
·
2023 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics
·
2012 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Chief, Division of Biostatistics
·
2019 - Present
Biostatistics & Bioinformatics,
Basic Science Departments
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
How To Interpret Subgroup Analyses from Prospective Randomized Clinical Trials: What Clinicians Need To Know.
Journal Article Eur Urol · January 2026 Subgroup analyses must be approached with caution. Only prespecified, well-powered analyses with formal interaction testing and validation can support strong claims; exploratory findings require confirmation. Integration of statistical rigor with clinical ... Full text Link to item CiteEffects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS.
Journal Article Cancer Med · January 2026 BACKGROUND: Darolutamide plus androgen-deprivation therapy (ADT) improved metastasis-free survival (MFS) by 2 years and reduced the risk of death by 31% in nonmetastatic castration-resistant prostate cancer (nmCRPC) in ARAMIS. Prior local therapy may influ ... Full text Link to item CiteEarly favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer.
Journal Article Nat Commun · December 17, 2025 There is an unmet need for a tool that could predict early favorable prostate-specific antigen (PSA) response in metastatic hormone sensitive prostate cancer (mHSPC) patients receiving androgen receptor pathway inhibitor (ARPI). Here, we train and validate ... Full text Link to item CiteRecent Grants
The COVID-19 and Cancer Consortium (CCC19) Registry
ResearchPrincipal Investigator · Awarded by Rhode Island Hospital · 2024 - 2029Assessing Prognoses and Validating Surrogate Endpoints for Clinical Outcomes in Metastatic Hormone Sensitive Prostate Cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2025 - 2028Research Triangle Center of Excellence in Regulatory Science and Innovation (CERSI)
ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028View All Grants
Education, Training & Certifications
University of Texas Health Sciences Center, Houston ·
1994
Ph.D.